Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients

Raphaella Cohen-Sors1 Dermatology Department, Amiens-Picardie University Hospital Center, Amiens, FranceView further author information

Anne-Claire Fougerousse2 Dermatology Department, Military Teaching Hospital Bégin, Saint-Mandé, France

Ziad Reguiai3 Dermatology Department, Polyclinic Courlancy, Reims, FranceView further author information

Francois Maccari2 Dermatology Department, Military Teaching Hospital Bégin, Saint-Mandé, FranceView further author information

Emmanuel Mahé4 Dermatology Department, Argenteuil Hospital, Argenteuil, France

Juliette Delaunay5 Dermatology Department, University Hospital, Angers, FranceView further author information

Aude Roussel2 Dermatology Department, Military Teaching Hospital Bégin, Saint-Mandé, FranceView further author information

Maud Amy de la Breteque4 Dermatology Department, Argenteuil Hospital, Argenteuil, FranceView further author information

Caroline Cottencin6 Dermatology Department, University Hospital, Lille, FranceView further author information

Antoine Bertolotti7 Dermatology Department, University Hospital, Saint-Pierre, Ile de la Réunion, FranceView further author information

Hélène Kemp8 Hematology Department, Amiens-Picardie University Hospital Center, Amiens, FranceView further author information

Guillaume Chaby1 Dermatology Department, Amiens-Picardie University Hospital Center, Amiens, FranceCorrespondence[email protected]
View further author information

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.